The absence of molecular amplification in proteomics and metabolomics means that researchers rely heavily on sensitive detection of a biomarker during analytical separation. In recent years, LC performance has been the limiting factor in such experiments as the incremental improvement of conventional columns stalls.
Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility, and robustness.
PharmaFluidics’ game-changing micro-chip based chromatography columns, with unprecedented analytical resolution performance, are now being used for cutting-edge bio-marker, diagnostics, and drug research & development applications in the global biotech and pharma industries.
The first µPAC™ columns were launched in 2017, and the company continues to build its portfolio based on the pillar array technology.
With offices in Ghent, PharmaFluidics is located at the heart of the Flanders life sciences valley. This biotech hub features a mix of world-renowned universities, knowledge centers, and biotech companies, giving the company direct access to talent, financing opportunities and a network of thriving companies.
Based on top-level academic research demonstrating the effects of order and disorder in particulate-based separation systems, PharmaFluidics introduces a new generation of chromatography columns. The company’s know-how is the design and manufacturing of miniaturized separation columns by silicon micromachining. The perfect order in the stationary phase leads to unique benefits in terms of performance, reproducibility, and robustness.
PharmaFluidics’ game-changing micro-chip based chromatography columns, with unprecedented analytical resolution performance, are now being used for cutting-edge bio-marker, diagnostics, and drug research & development applications in the global biotech and pharma industries.
The first µPAC™ columns were launched in 2017, and the company continues to build its portfolio based on the pillar array technology.
With offices in Ghent, PharmaFluidics is located at the heart of the Flanders life sciences valley. This biotech hub features a mix of world-renowned universities, knowledge centers, and biotech companies, giving the company direct access to talent, financing opportunities and a network of thriving companies.
Location: Belgium, East Flanders, Zwijnaarde
Employees: 11-50
Total raised: $8.79M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Heran Part... | heranpartn... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.01.2018 | - | $8.79M | - |
Mentions in press and media 4
| Date | Title | Description |
| 25.03.2022 | Qbic establishes third fund | St-Denijs-Westrem, Belgium, 17 March 2022 – Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, announces the first close of its third fund at € 49 millio... |
| 20.12.2021 | Intertrust N : Why investors should check out Belgium's world-leading biotech industry | Make an enquiry The country's industrial heritage allied with strong government incentives to help it play a leading role in the race to develop Covid vaccines, say Business Development Manager Brecht Guldemont and Managing Director Christo... |
| 09.11.2021 | PharmaFluidics acquired by Thermo Fisher Scientific | |
| 11.01.2018 | PharmaFluidics Raises €7.3M in Funding | PharmaFluidics NV, a Ghent, Belgium-based analytical chromatography company, raised €7.3m in funding. Backers included holding company FPIM-SFPI, family offices Heran (Annie Vereecken) and RMM (Rudi Mariën) and existing investors PMV, Qbic,... |